At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 70 enrolled
Drug / intervention
VRC-HIVADV014-00-VPbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I Clinical Trial to Evaluate the Safety of a Multiclade Recombinant Adenoviral Vector HIV-1 Vaccine Administered to Healthy, HIV-1 Uninfected, Adult Participants Who Received DNA Plasmid Vaccine or Placebo in the HVTN 052 Clinical Trial
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Sep 9, 2004·Updated Oct 14, 2021
In Brief
A Phase 1 clinical trial evaluating VRC-HIVADV014-00-VP for HIV Infections. Completed, enrolled 70 participants across 8 sites.
Detailed Summary
The purpose of this study is to test the safety of and immune response to an HIV-1 vaccine, VRC-HIVADV014-00-VP, when given as a vaccine booster to HIV uninfected adults who participated in HVTN 052.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 2004
Study CompletionMay 2006
TodayJul 2026
First PostedSep 9, 2004
Study CompletionMay 1, 2006
TodayJul 2, 2026
Posted 21.8 years ago
Interventions
VRC-HIVADV014-00-VPbiological